---
title: "MicroPort Affiliate Endovastec Posts 2025 Revenue Growth to RMB1.35 Billion"
description: "MicroPort Scientific Corporation's affiliate, Endovastec, reported unaudited 2025 revenue of RMB 1.35 billion, marking an 11.96% increase year-on-year. The company achieved a profit of RMB 653.37 mill"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/277192080.md"
published_at: "2026-02-27T11:47:52.000Z"
---

# MicroPort Affiliate Endovastec Posts 2025 Revenue Growth to RMB1.35 Billion

> MicroPort Scientific Corporation's affiliate, Endovastec, reported unaudited 2025 revenue of RMB 1.35 billion, marking an 11.96% increase year-on-year. The company achieved a profit of RMB 653.37 million, with a net profit attributable to equity owners of RMB 563.21 million. As of December 31, 2025, total assets reached RMB 4.64 billion, and equity attributable to owners rose to RMB 4.08 billion.

MicroPort Scientific Corporation said its affiliate Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. (Endovastec), in which it holds a 40.32% stake, reported unaudited 2025 revenue of RMB 1.35 billion, up 11.96% year on year. Endovastec posted profit of RMB 653.37 million and net profit attributable to equity owners of RMB 563.21 million, while total assets rose to RMB 4.64 billion and equity attributable to owners increased to RMB 4.08 billion as of Dec. 31, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MicroPort Scientific Corporation published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260227-12032600), on February 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### Related Stocks

- [02252.HK - MircroPort Medbot-B](https://longbridge.com/en/quote/02252.HK.md)
- [159898.CN - China Merchants CSI All Share Medical Apparatus and Instruments ETF](https://longbridge.com/en/quote/159898.CN.md)
- [02172.HK - MICROPORT NEURO](https://longbridge.com/en/quote/02172.HK.md)
- [02160.HK - MP CARDIOFLOW-B](https://longbridge.com/en/quote/02160.HK.md)
- [00853.HK - MICROPORT](https://longbridge.com/en/quote/00853.HK.md)
- [562600.CN - ChinaAMC CSI All Share Health Care Devices ETF](https://longbridge.com/en/quote/562600.CN.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| MicroPort Scientific Deconsolidates NeuroScientific Corporation After Board Changes | MicroPort Scientific Corporation has deconsolidated MicroPort NeuroScientific Corporation after appointing an independen | [Link](https://longbridge.com/en/news/271118349.md) |
| Shandong Weigao Orthopaedic Device posts Shanghai Stock Exchange announcement | Shandong Weigao Group Medical Polymer Co. Ltd. announced that its affiliate, Shandong Weigao Orthopaedic Device Company  | [Link](https://longbridge.com/en/news/277191160.md) |
| 13:35 ETNational Research Initiative Launches to Explore Human-AI Collaboration in Online Program Design | Quality Matters (QM) has launched a multi-year research initiative in collaboration with iDesign to explore how AI can e | [Link](https://longbridge.com/en/news/276775347.md) |
| 16:01 ETDataJoint Launches Agentic AI Control Layer for Scientific Workflows, Enabling Defensible and Reproducible AI in Regulated R&D | DataJoint has launched DataJoint Agentic AI, a governed execution layer for scientific workflows that enhances the relia | [Link](https://longbridge.com/en/news/276936216.md) |
| MicroPort CardioFlow Merges with MicroPort CRM | MicroPort CardioFlow has merged with MicroPort CRM to create a comprehensive platform focused on structural heart, cardi | [Link](https://longbridge.com/en/news/275426231.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.